Myeloid to utilize MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to advance its novel cell therapies to treat solid tumors, T cell lymphoma and glioblastoma CAMBRIDGE, MA and GAITHERSBURG, MD, January 11, 2021 — Myeloid Therapeutics, Inc., a company harnessing and reprogramming
Gaithersburg, Maryland – October 15, 2019: MaxCyte, the global cell-based therapies and life sciences company, announces its planned participation at the BIO Investor Forum in San Francisco, California. CEO & President Doug Doerfler will present 22 October at 11:15 a.m.
Gaithersburg, Maryland – October 2, 2019: MaxCyte, the global cell-based therapies and life sciences company, announces today its planned participation at key upcoming industry conferences. These conferences and events will provide an opportunity for MaxCyte to showcase how the Company is driving
Dhana Chinnasamy, PhD, will oversee non-clinical and translational activities for MaxCyte’s autologous cell therapy platform for targeted cell-based immune therapies Gaithersburg, Maryland – July 23, 2019: MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announced
Gaithersburg, Maryland – March 18, 2019: MaxCyte announced today that Debra K. Bowes , Chief Business Officer, CARMA™ Cell Therapy, will present “Novel mRNA-based Autologous CAR Therapies in Oncology” at two upcoming industry conferences. The 13th Annual International Partnering Conference
Gaithersburg, Maryland – December 19, 2018: MaxCyte announced today that Debra K. Bowes , Chief Business Officer, CARMA™ Cell Therapy, and Claudio Dansky Ullmann , MD, Chief Medical Officer, will present on the company’s CARMA platform at two upcoming industry conferences: the Biotech Showcase
Gaithersburg, Maryland – October 30, 2018: MaxCyte announced today that Debra K. Bowes , Chief Business Officer, CARMA Cell Therapy, will present “Novel mRNA-based Autologous CAR Therapies in Oncology” at the 24th Annual International Partnering Conference BIO-EUROPE.
Gaithersburg, Maryland – August 29, 2018 – MaxCyte announced today that Debra K. Bowes, Chief Business Officer, CARMA Cell Therapy, will present “Novel mRNA-based Autologous CAR Therapies in Oncology” at two upcoming industry conferences. On September 5, 2018, at 2:45 p.m.
Gaithersburg, Maryland – January 2, 2018 : MaxCyte announced today that Debra K. Bowes, Executive Vice President, Business and Strategic Development , will present at two life sciences conferences this month: the Biotech Showcase on January 8 at 3:30 p.m.
Gaithersburg, Maryland – September 14, 2017 : MaxCyte, a US-based global company driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines, announced today that Madhusudan V. Peshwa, PhD, MaxCyte Chief Scientific Officer,
